Wells Fargo Initiates Coverage On Myriad Genetics with Overweight Rating, Announces Price Target of $35
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo has initiated coverage on Myriad Genetics with an Overweight rating and set a price target of $35.
August 27, 2024 | 10:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wells Fargo has initiated coverage on Myriad Genetics with an Overweight rating and a price target of $35, indicating a positive outlook.
The initiation of coverage with an Overweight rating by Wells Fargo suggests a positive sentiment towards Myriad Genetics. The price target of $35 indicates potential upside, which is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100